StockStory.org on MSN2d
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...
the estimate revisions trend for Supernus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status ...
Reports Q4 revenue $174.2M ... and strong growth in operating earnings,” said Jack Khattar, President and CEO of Supernus (SUPN). “In 2025, we look forward to continued Qelbree growth ...
StockStory.org on MSN20d
What To Expect From Supernus Pharmaceuticals’s (SUPN) Q4 EarningsIs Supernus Pharmaceuticals a buy or sell going into earnings? Read our full analysis here ... Click here to claim your Special Free Report on a fallen angel growth story that is already recovering ...
Zacks.com on MSN18d
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue EstimatesSupernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results